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ReviewThe Function and Therapeutic Potential of Long
Non-coding RNAs in Cardiovascular
Development and Disease
Clarissa P.C. Gomes,1 Helen Spencer,2 Kerrie L. Ford,3 Lauriane Y.M. Michel,4 Andrew H. Baker,2
Costanza Emanueli,3,5 Jean-Luc Balligand,4 and Yvan Devaux1 on behalf of the Cardiolinc network
1Cardiovascular Research Unit, Luxembourg Institute of Health, 1526 Luxembourg, Luxembourg; 2Centre for Cardiovascular Science, University of Edinburgh, Edinburgh
EH8 9YL, UK; 3Bristol Heart Institute, University of Bristol, Bristol BS8 1TH, UK; 4Unité de Pharmacologie et de Thérapeutique, Institut de Recherche Experimentale et
Clinique, Université Catholique de Louvain, 1348 Louvain-la-Neuve, Belgium; 5National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UKThe popularization of genome-wide analyses and RNA
sequencing led to the discovery that a large part of the human
genome, while effectively transcribed, does not encode pro-
teins. Long non-coding RNAs have emerged as critical regula-
tors of gene expression in both normal and disease states.
Studies of long non-coding RNAs expressed in the heart, in
combination with gene association studies, revealed that these
molecules are regulated during cardiovascular development
and disease. Some long non-coding RNAs have been function-
ally implicated in cardiac pathophysiology and constitute
potential therapeutic targets. Here, we review the current
knowledge of the function of long non-coding RNAs in the car-
diovascular system, with an emphasis on cardiovascular devel-
opment and biology, focusing on hypertension, coronary artery
disease, myocardial infarction, ischemia, and heart failure. We
discuss potential therapeutic implications and the challenges of
long non-coding RNA research, with directions for future
research and translational focus.http://dx.doi.org/10.1016/j.omtn.2017.07.014.
Correspondence: Yvan Devaux, Cardiovascular Research Unit, Luxembourg
Institute of Health, 84 Val Fleuri, 1526 Luxembourg, Luxembourg.
E-mail: yvan.devaux@lih.lu;New sequencing technologies, combined with bioinformatics and
computational tools, have allowed the scientiﬁc community to appre-
ciate the great complexity of the transcriptome.1 In particular, the dis-
covery of various types of non-protein coding RNAs (ncRNAs) and
their different functions in regulating developmental and disease pro-
cesses is expanding our knowledge of molecular biology and could
signiﬁcantly advance therapeutic options formany patients, including
those suffering from cardiovascular disease. Thousands of ncRNAs
have been described and classiﬁed into two large groups: small
ncRNAs, which are up to 200 nucleotides long, and long non-coding
RNAs (lncRNAs), which are longer than 200 nucleotides.
lncRNAs are a heterogeneous group of transcripts exerting major reg-
ulatory roles in gene expression, and their importance in cardiovascular
disease has been reinforced.2,3 The dynamic expression and speciﬁc
proﬁles of lncRNAs in different pathophysiological states suggest their
functional relevance and potential to be used as non-invasive markers
of disease and therapeutic targets.4,5 However, establishing the biolog-
ical actions of each lncRNA is provingmore complex than investigating494 Molecular Therapy: Nucleic Acids Vol. 8 September 2017 ª 2017 T
This is an open access article under the CC BY-NC-ND license (httpmicroRNAs (miRNAs, the most popular class of small ncRNAs within
the biomedical community). This is due to lncRNAs’ multiple modal-
ities of action and their low conservation among vertebrates.6 There-
fore, a large gap remains between the number of lncRNAs identiﬁed,
and then listed in databases, and their functional characterization and
implications in pathophysiological situations. A list of databases and
theirmajor characteristics, such as number of lncRNAs, species, and as-
sociation with function and other genes, is given in Table 1.
So far, it has been demonstrated that lncRNAs can regulate gene
expression through functional mechanisms including epigenetic,
transcriptional, and post-transcriptional, either activating or sup-
pressing gene expression. lncRNAs can also mediate signaling, such
as phosphorylation, and trafﬁcking of proteins.7,8 One way to classify
lncRNAs is according to their mechanism of action: signal, decoy,
guide, scaffold,9 enhancer, or sponge lncRNAs (particularly circular
lncRNAs [circRNAs]) (Figure 1).10,11 In this review, we do not
address in detail the lncRNAs mechanisms of action but instead refer
to reviews on the subject.2,12–14
A growing number of lncRNAs are implicated in cardiovascular
development and disease, although it is not clearly understood how
they participate in pathological processes. Their potential as thera-
peutic targets has often been raised, and there are a few examples
of in vivo modulation of lncRNAs. However, modulating lncRNAs
has been a challenging task to date.15–19 Here, we summarize the cur-
rent understanding of lncRNA function in cardiovascular pathophys-
iology and discuss its potential for therapy.Function of lncRNAs in the Cardiovascular System
Cardiac Development and Biology
Transcriptomics proﬁling and loss-of-function approaches in pro-
genitor and embryonic stem cells (ESCs) have demonstrated thehe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. List of Available Databases on lncRNAs
Database What Species No. of lncRNAs
Last
Update
Association
with
Function
Association
with Protein-
Coding RNAs
Association
with miRNAs Reference
ANGIOGENES
in silico screening of protein-coding
genes and lncRNAs in ECs
human, mouse,
zebraﬁsh
24,382 (15,149 in
human)
2016 X 164
ChIPBase
transcriptional regulation of lncRNA
from ChIP-seq data
10
10,200 ChIP-seq
datasets
2016 X 165,166
deepBase
identiﬁcation, annotation, and
function prediction of lncRNAs from
RNA-seq data
14 191,547 2016 X 167,168
GENCODE
manually curated human and mouse
lncRNA reference based on ENCODE
project
human, mouse 42,302 2016 169,170
LincSNP
annotated disease-associated SNPs in
human lncRNAs
human 244,545 2016 X 171
LNCipedia
annotated lncRNA sequences,
structures, protein coding potential,
and miRNA binding sites
human 118,777 2016 X X 172,173
lncRNAdb
curated reference database of
functionally annotated eukaryotic
lncRNAs
71
295 (183 in
human)
2015 X 174,175
LncRNADisease
experimentally supported and
predicted associations between
lncRNAs and diseases
human 1,564 2015 X 176
lncRNome annotated human lncRNAs human 17,547 2013 X X X 177
NONCODE
integrated annotation of ncRNAs,
especially lncRNAs
16
487,164 (167,150
in human)
2016 X X 178
ChIP-seq, chromatin immunoprecipitation sequencing.
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Reviewimportance of lncRNAs for cardiac development and cell differentia-
tion. More than 1,000 lncRNAs were reported as being dynamically
regulated during differentiation,20,21 and further transcriptome ana-
lyses of embryonic and adult-stage murine hearts identiﬁed several
lncRNAs speciﬁc to tissue and developmental stage.22,23
Among biologically validated lncRNAs, several have been associated
with cardiac development (Table 2). For example, Braveheart (Bvht)
has a critical role in cardiac lineage commitment in mouse. It is abun-
dantly expressed in embryonic stem cells and regulates the transition
from nascent mesoderm to cardiac progenitor.24 Bvht, by modulating
the core cardiovascular gene network and mediating the epigenetic
regulation of cardiac fate, is necessary to maintain cardiac commit-
ment.25 Conversely, the lateral mesoderm-speciﬁc lncRNA Fendrr
(fetal-lethal non-coding developmental regulatory RNA) controls
mesodermal differentiation, as well as heart and body wall develop-
ment, by binding to the histone-remodeling polycomb repressive
complex PRC2 and TrxG/MLL to modulate chromatin status.26
Numerous enhancer-associated lncRNAs have been implicated in
cardiogenic differentiation,21,27 among which the enhancer lncRNA
Novlnc6modulates expression of MKX2.5, a transcription factor crit-
ical for cardiac differentiation and maturation.27 CARMEN (cardiac
mesoderm enhancer-associated non-coding RNA) is also responsiblefor cardiogenic speciﬁcation and differentiation in precursor cells,
possibly by regulating PRC2.28 Furthermore, several lncRNAs regu-
late speciﬁc mRNA abundance during heart development, although
as yet there is no clear understanding of their role during cardiogenic
differentiation. For example, n411949 regulatesMccc1mRNA, which
metabolizes leucine, and n413445 modulates ReIb, which is involved
in the nuclear factor kB (NF-kB) pathway.22 Overall, fetal gene pro-
gram reactivation constitutes a hallmark in multiple cardiovascular
diseases. Although a moderate number of dynamically regulated
lncRNAs in embryonic cells are equally regulated in the hypertrophic
heart,22 some lncRNAs associated with cardiac pathologies may also
be implicated in cardiac development.27 As for cell proliferation, a
study identiﬁed eight lncRNAs putatively implicated in the prolifera-
tive capacity of cardiac cells in fetal heart29 that require further
investigation.
Cardiomyocyte repolarization during the ﬁnal stage of the action po-
tential needs potassium ﬂuxes mediated by the Kv7.1 channels. In
late embryogenesis, lncRNA Kcnq1ot1 (potassium voltage-gated
channel, KQT-like subfamily, member 1 opposite strand/antisense
transcript 1) regulates the expression of the transcript Kcnq1, which
encodes the potassium channel Kv7.1.
30 Such regulation fulﬁlls the
requirement for increased cardiac contractile activity in this late
developmental stage. Dysregulation of KCNQ1OT1 expression hasMolecular Therapy: Nucleic Acids Vol. 8 September 2017 495
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Figure 1. Classification of lncRNAs by Mechanism of
Action
Signal lncRNAs respond to specific stimuli and thus show
expression specific to cell type. Decoys bind transcription
factors and other proteins away from their target site, re-
pressing transcription. Guides interact with regulatory
proteins, forming ribonucleoprotein complexes, and direct
them to their target sites in subcellular locations. Scaffolds
serve as platforms to bring different proteins together, both
in the cytoplasm and in the nucleus, activating or re-
pressing transcription. Enhancers are regulatory se-
quences in which transcription factors bind to initiate
transcription; these regions of the genome produce several
transcripts, enhancer lncRNAs, which act in cis to regulate
expression of target genes. In the cytoplasm, lncRNAs can
activate or inhibit translation by binding to target mRNAs.
They can also regulate protein trafficking and signaling,
such as phosphorylation. Sponging miRNAs is another way
lncRNAs (including circular RNAs) regulate gene expres-
sion post-transcriptionally.
www.moleculartherapy.org
Reviewbeen associated with left ventricular (LV) dysfunction after myocar-
dial infarction (MI),31 thereby potentially linking this lncRNA to car-
diac contractility and arrhythmia in a clinical setting.
A switch in myosin heavy chain (MHC) isoforms accompanies the
acquisition of the adult cardiac contractile phenotype. The expression
of a-MHC in adult left and right ventricles is associated with higher
ﬁlament sliding velocity, while the slower b-MHC confers higher
force at lower energy cost.32 In rodent models (which mainly express
the a-MHC isoform in the normal adult stage), the intergenic region
between the two genes has been shown to regulate the transition from
b- to a-MHC during cardiac development through co-transcription
of an antisense RNA, called b-RNA, targeting and inhibiting the
myosin heavy chain 7 (MYH7) transcript (encoding the b-MHC iso-
form).33,34 This mechanism is responsive to thyroid status and further
implicated in the response to pressure overload.35,36496 Molecular Therapy: Nucleic Acids Vol. 8 September 2017Vascular Development and Biology
Growing evidence describes lncRNAs as key
molecular players of vascular and endothelial
cell (EC) biology. SENCR (smooth muscle and
EC-enriched migration/differentiation-associ-
ated lncRNA) was among the ﬁrst lncRNAs to
be identiﬁed in human vascular smooth muscle
cells (VSMCs) and ECs, being involved in their
differentiation.37,38 The lncRNA SMILR (smooth
muscle-induced lncRNA) appears to promote
VSMC proliferation and may achieve this by
regulating expression of adjacent transcripts,
HAS2 (hyaluronan synthase 2).39 HAS2 plays a
role in proliferation in saphenous vein-derived
VSMCs, in which small interfering RNA (siRNA)
targeting of HAS2 resulted in reduced prolifera-
tion ability.40 SMILR could be a target for therapy
of atherosclerosis because VSMC aberrant func-tion is one of the deﬁning features of atherosclerotic plaques (see Cor-
onary Artery Disease and Atherosclerosis). MALAT1 (metastasis-
associated lung adenocarcinoma transcript 1) is one of the most
abundant lncRNAs in mammalian cells, and it was observed in
ECs. Due to its increased expression in hypoxia,MALAT1 is proposed
to have a role in vascularization, although knockout mice did not pre-
sent severe developmental abnormalities.17 MALAT1 is involved in
alternative splicing41 and possibly regulates gene expression during
vascular development and disease.17
In vitro differentiation of embryonic stem cells can recapitulate the
development process, with transcriptome studies being employed to
identify novel lncRNAs whose role is important for either commit-
ment of cardiovascular progenitors or endothelial commitment.38,42
A study that identiﬁed hundreds of novel ncRNA transcripts in the
vascular setting functionally characterized the lncRNA PUNISHER,
Table 2. lcnRNAs Associated with Cardiovascular Biology
lncRNA Expression Biological Context Action
Genomic
Localization Organism Reference
Differentiation and Cardiac Development
Bvht embryonic stem cells cardiomyocyte differentiation signal intergenic mouse 24,25
Fendrr lateral plate mesoderm development of heart and body wall signal intergenic human, mouse, rat 26
Novlnc6
embryonic stem cells
(particularly left ventricle),
cardiomyocytes
cardiac differentiation and maturation decoy human, mouse 27
CARMEN cardiac precursor cell
cardiomyocyte differentiation of cardiac
precursor cells
enhancer intergenic human, mouse, rat 28
n411949 embryonic heart cardiac development unknown antisense mouse 22
n413445 embryonic heart cardiac development unknown intronic mouse 22
Contractile Function
KCNQ1OT1 cardiac development signal antisense human, mouse 30
b-RNA adult ventricles contractile phenotype, pressure overload unknown antisense rat 33
Vascular Development
SENCR smooth muscle cells
maintenance of smooth muscle cells’
differentiated state
decoy antisense human 37,38
SMILR VSMCs proliferation of smooth muscle cells
proposed
scaffold or
enhancer
intergenic human 39
MALAT1 ECs proliferation of ECs and vascularization decoy intergenic human, mouse 17
PUNISHER ECs identity of ECs guide antisense
human, mouse,
zebraﬁsh
42
www.moleculartherapy.org
Reviewwhich is expressed in mature ECs.42 Morpholino targeting of
PUNISHER in zebraﬁsh culminated in extensive vascular defects,
including abnormal branching and vessel formation. PUNISHER
silencing in human umbilical vein ECs (HUVECs) using short hairpin
RNA (shRNA) revealed similar defects. Overall, PUNISHER compro-
mises EC function, but its mechanism of action or its involvement in
vascular pathologies have not yet been elucidated.42
lncRNAs in Cardiovascular Disease
The association between lncRNAs and cardiovascular disease is just
coming to light with several reports about their speciﬁc expression
in different cardiac diseases. Dysregulation of certain lncRNAs has
been shown in both human and rodent models (Figure 2), in which
some studies present encouraging results for disease prognosis and
therapy. The biological context of lncRNAs discussed in this section
is illustrated in Figure 3. However, because of their poor conservation
across species, translation of animal ﬁndings to human applications
should be approached with caution. Here we overview the role of
lncRNAs in hypertension, coronary artery disease (CAD), MI,
ischemia, and heart failure.
Some lncRNAs differentially expressed during cardiovascular devel-
opment also participate in a pathological setting, while others are
involved in more than one cardiovascular disease. SENCR and H19,
for example, are widely implicated in cardiovascular disease. SENCR,
besides playing a role in VSMC and EC differentiation during devel-opment, has also been suggested to affect CAD. This lncRNA was
found to be downregulated in VSMCs from a type 2 diabetes mellitus
murine model, promoting proliferation and migration.43 In addition,
SENCR overexpression protected against the effects of high glucose
stress on mouse VSMCs,43 and its reduced expression has been asso-
ciated with premature CAD in humans.38
H19 is an important regulator of mammalian development and dis-
ease in that it inhibits cell proliferation.44 It is normally highly ex-
pressed during in utero development and downregulated at birth;
however, studies reveal a re-expression of lncRNA H19 in cardiovas-
cular disease settings, although not all mechanisms and involved
players have been described.45–53 Human genome-wide association
studies (GWASs) have demonstrated signiﬁcant associations between
H19 locus and systolic or mean arterial blood pressure.54 High H19
expression has been linked to hyperhomocysteinemia, a known risk
factor for CAD,45,51 and polymorphisms correlate with CAD risk.47
Methylation at the IGF2/H19 locus have been implicated in regula-
tion of glucose metabolism and development of diabetes,46,53,55 renal
development,56 pre-eclampsia,57 and aortic stenosis,58 indicating
possible links. Furthermore, H19 was reported to sponge let-7 family
miRNAs,59 which are believed to have atheroprotective60–63 or proa-
therosclerotic64 roles and are downregulated in CAD patients.65 In
addition, H19 was identiﬁed as differentially expressed in normoxic
versus hypoxic ECs.66 Finally, it is a precursor of miR-675, which
inhibits cardiomyocyte hypertrophy52 and contributes to cardiacMolecular Therapy: Nucleic Acids Vol. 8 September 2017 497
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Figure 2. lncRNAs that Are Up- or Downregulated in Cardiovascular Diseases
The human, mouse, or rat symbol indicates in which organism the lncRNA has been described. *MIAT is downregulated in ST-elevationmyocardial infarction (STEMI) patients
compared to non-ST-elevation myocardial infarction (NSTEMI) patients; it correlates with hypertension, but there is no change in regulation.
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Reviewﬁbroblast proliferation and ﬁbrosis, acting through repression of
DUSP5/ERK1/2 (Figure 4).67
Hypertension
Hypertension has a complex etiology, involving an interplay of envi-
ronmental and genetic components, and is a major risk factor for
other cardiovascular diseases. Although many miRNAs have been
shown to act in the pathogenesis of hypertension,68 reports on
lncRNAs that relate to hypertension are scarce. However, studies
based on animal and cell models in this area are emerging. One
lncRNA involved in hypertension and vascular remodeling is GAS5
(growth arrest-speciﬁc 5).69 GAS5 was found to be downregulated
in the plasma of human hypertensive patients and in the arteries
and retina of a rat model, the spontaneously hypertensive rat. In these
rats, GAS5 knockdown exacerbated the hypertensive phenotype,
arterial remodeling, and microvascular dysfunction.69 In HUVECs
and VSMCs, proliferation, migration, and resistance to oxidative
stress were altered by GAS5 siRNAs. Co-culture experiments sug-
gested that GAS5 participates in extracellular vesicle-mediated
cross-talk between ECs and VSMCs.
A screening approach using angiotensin II (Ang II)-treated rat
VSMCs identiﬁed differentially expressed lncRNAs, one of which,
lnc-Ang362, is proximal to miR-221 and miR-222.70 These two
miRNAs, which regulate the proliferation of rat VSMCs71 and the498 Molecular Therapy: Nucleic Acids Vol. 8 September 2017migration of HUVECs,72 were also upregulated in response to Ang
II and appeared to be co-transcribed with the lncRNA. Consistently,
lnc-Ang362 siRNA knockdown decreased miR-221/222 expression
and reduced VSMCs proliferation.70 Thus, together with miR-221/
222, lnc-Ang362 may represent an interesting therapeutic target
that deserves further investigation, because it is conserved in human.
Given the poor evolutionary conservation of many lncRNAs, any
approach based solely on animal models may limit discovery. In a
cohort of patients with acute MI, expression of four lncRNAs—
ANRIL (antisense non-coding RNA in the INK4 locus), aHIF (hypox-
ia-inducible factor 1A antisense RNA 2),MIAT (MI-associated tran-
script), and MALAT1—was found to be signiﬁcantly associated with
hypertension.31 Although their mechanisms of action in hypertension
are not yet described, ANRIL affects cell adhesion, proliferation, and
apoptosis,73 and MALAT1 modulates EC migration, sprouting, and
proliferation.17 A novel bioinformatics tool, LncDisease, has been
used to predict four human lncRNAs associated with hypertension,
three of which were validated as dysregulated in Ang II-treated hu-
man VSMCs.74 Further investigation is required to ﬁrmly establish
their validity in human hypertension.
CAD and Atherosclerosis
Atherosclerosis is typiﬁed by the formation of a ﬁbro-fatty plaque in
the arterial vessel wall and involves the molecular and functional
Cell proliferation
Pro-hypertrophic
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Figure 3. Biological Context of lncRNAs Associated with Cardiovascular Disease and Their Mechanism of Action
CAD, coronary artery disease; MI, myocardial infarction.
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Reviewdysregulation of ECs, VSMCs, macrophages and other leukocytes,
and platelets.75 When atherosclerosis occurs in the epicardial vessels
of the heart, it is referred to as CAD, which is a leading cause of death
worldwide. Dysregulated expression of speciﬁc lncRNAs has been re-
ported to contribute to CAD.
The lncRNA RNCR3 (retinal non-coding RNA 3) expression is
altered during atherosclerosis, being overexpressed in atherosclerotic
VSMCs and ECs compared with non-atherosclerotic tissue in mouse
and human.76 Compared with control mice, downregulation of
RNCR3 with shRNA aggravated atherosclerosis in thoracic aorta tis-
sue and increased inﬂammatory factors in plasma. In vitro treatment
with oxidized low-density lipoprotein (ox-LDL) increased RNCR3
levels in HUVECs and VSMCs, reducing proliferation and viability
and increasing apoptosis. These data suggest that RNCR3 is athero-
protective. Moreover, the same study demonstrated in vitro that exo-
somes derived from ECs are rich in RNCR3, which is transferred to
VSMCs and induces their proliferation and migration. The proposed
mechanism of action in ECs is that RNCR3 regulates the transcription
factor KLF2 by sponging miR-185-5p, which targets KLF2.
Thus because of the atheroprotective role of RNCR3 in atheroscle-
rosis, its induced upregulation potentially represents a therapeutic
intervention.76
LincRNA-p21 was identiﬁed as a transcriptional target of p53.77 In
VSMCs, this lncRNA disrupted the binding between p53 and its in-
hibitor, mouse double minute 2 (MDM2), with consequent effects
on cell proliferation and apoptosis.78 LincRNA-p21 protected againstneointimal hyperplasia in the carotid artery injury mouse model and
was downregulated in aortic atherosclerotic plaques and in coronary
artery tissues from CAD patients.78 Furthermore, polymorphisms in
lincRNA-p21 have been associated with CAD risk.79 The therapeutic
potential of lncRNA-p21 in acute vascular injury is suggested by its
regulatory role of cell proliferation and apoptosis in CAD.
Remodeling of the extracellular matrix and neointimal formation are
additional key features of CAD. Deposition of hyaluronan, synthe-
sized by HAS2, contributes to this process. Two lncRNAs indepen-
dently regulate HAS2: HAS2-AS1 (HAS2 antisense RNA 1) and
SMILR. The antisense transcriptHAS2-AS1 was increased in atherec-
tomy samples collected from severely diseased carotid arteries and
appears to promote HAS2 transcription in VSMCs in the presence
of O-GlcNAcylation by altering chromatin conﬁguration.80 This
may be particularly relevant to neointimal formation in diabetic pa-
tients. SMILR, which promotes VSMC proliferation, was signiﬁcantly
upregulated in VSMCs stimulated with interleukin 1a and platelet-
derived growth factor compared to unstimulated cells. In addition,
its levels in plasma correlated with the inﬂammatory marker C-reac-
tive protein and were upregulated in human carotid artery atheroscle-
rotic plaques compared with adjacent healthy tissue.39
Several other lncRNAs have been associated with inﬂammation,81–88
including in the context of diabetes,89–91 although direct links to CAD
remain to be established. Downregulation of the lncRNA termed
CoroMarker, originally identiﬁed as a biomarker of CAD,92 has
been shown to decrease pro-inﬂammatory cytokine secretion fromMolecular Therapy: Nucleic Acids Vol. 8 September 2017 499
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www.moleculartherapy.org
ReviewTHP-1 monocytic cells,93 while ANRIL has been linked to the inﬂam-
matory response in ECs.94 CoroMarker, for instance, is a prominent
example of lncRNA as biomarker for CAD, because it correctly iden-
tiﬁed with high sensitivity most CAD patients in a large cohort.92
MI and Ischemia
Although advances in treatment and diagnosis of MI have increased
patient survival and quality of life, MI is still a major cause of mortal-
ity and morbidity worldwide.95 Several lncRNAs have been uncov-
ered as being dysregulated in MI, and some may play roles in patho-
logical angiogenesis and ischemic cardiac injury. Several GWASs have
revealed an association between the INK4 locus and the risk of CAD,
including MI. This locus is important for cell-cycle progression and
cell growth and encodes tumor-suppressor genes CDKN2A and
CDKN2B and the lncRNA ANRIL.96–98 Several linear and circular
isoforms of ANRIL have been identiﬁed, and their expression differs
according to speciﬁc tissues and disease conditions.99,100 Despite
contradictions in the literature regarding its mechanisms of ac-
tion,73,101–105 there is a consensus that ANRIL affects cell prolifera-
tion.73,101–103,106,107 Moreover, increased blood circulating ANRIL
expression was associated with LV dysfunction.31 The same study
identiﬁed the lncRNAsMIAT andMALAT1 as similarly associated.31
A large-scale GWAS identiﬁedMIAT and six variants in its locus that
confer susceptibility to MI. One variant was associated with upregu-
lation of MIAT expression.108 So far, the molecular mechanisms by
which this lncRNA regulates MI remain largely unknown, although
it may be involved in alternative splicing in the diseased heart.109
In a mouse model of MI induced by coronary ligation, several
lncRNAs were dysregulated in the heart, among which the two
most strongly upregulated were namedMirt1 andMirt2 (myocardial
infarction-associated transcript 1 and 2).110 Their levels peaked 24 hr
after MI and returned to baseline after 2 days, indicating that
lncRNAs may be dynamically regulated in pathological processes.
Mirt1 and Mirt2 levels correlated with expression of genes involved500 Molecular Therapy: Nucleic Acids Vol. 8 September 2017in reversing LV remodeling and preserved ejection fraction, suggest-
ing a protective role in LV function. This study evidenced a therapeu-
tic potential of these two lncRNAs. However, no human homologs of
Mirt1 and Mirt2 have been described so far.
In addition to their potential as therapeutic targets, lncRNAs could
serve as clinical biomarkers. One of the ﬁrst studies to provide
evidence of the feasibility of using lncRNAs as biomarkers for cardio-
vascular disease identiﬁed and validated LIPCAR (long intergenic
non-coding RNA predicting cardiac remodeling) in a large number
of patients.111 LIPCAR levels were increased in plasma samples
from patients with LV remodeling after acute MI111 and in patients
with type 2 diabetes mellitus.112 Circulating LIPCAR may also have
prognostic value because its levels correlated with higher mortality
risk in patients with heart failure. LIPCAR’s therapeutic potential re-
mains to be investigated.
Myocardial infarction-associated circular RNA (MICRA) was the ﬁrst
circRNA to be identiﬁed as a potential biomarker of LV dysfunction
after MI, with its predictive value conﬁrmed in two independent co-
horts.113 Therapeutic applications for this circRNA are yet to be
discovered. A few circRNAs with relevance to cardiovascular disease
have been unveiled and reviewed.114–117 For example, Cdr1as (cere-
bellar degeneration-related protein 1 antisense transcript) was uncov-
ered as a miR-7a sponge in cardiomyocytes, showing upregulation in
MI mice and cardiomyocytes under hypoxia.118
The lncRNA UCA1 (urothelial carcinoma-associated 1), proposed as
a biomarker as well, presented altered expression in MI patients.119 In
rats with ischemia and reperfusion (I/R)-induced heart injury,
another study found that UCA1 contributes to cardiac injury by
enhancing apoptosis of cardiomyocytes.120 However, its application
as a biomarker seems limited, because it performed worse than clas-
sical markers of MI (e.g., creatine kinase).119 Nonetheless, because it
has a role in I/R injury, future studies could reveal a therapeutic
www.moleculartherapy.org
Reviewpotential to UCA1. Another lncRNA playing a role in the heart
response to ischemia is HIF1A-AS2, also known as aHIF. It destabi-
lizes the mRNA producing the hypoxia-inducible factor 1-a
(HIF1a), which is considered the master transcriptional regulator
of cellular response to hypoxia, including post-ischemic angiogen-
esis.121 Besides being overexpressed in the failing heart,121 aHIF
was found to be dysregulated in the blood of patients after MI.31
Although a certain level of autophagy has been shown to be cardio-
protective in ischemia,122 reports suggest that the accumulation of au-
tophagosomes can trigger cardiomyocyte death, particularly during
post-ischemic reperfusion.123,124 The lncRNA APF (autophagy-pro-
moting factor) participates in the regulation of autophagy and MI
in mice.125 APF is increased during I/R injury and sequesters miR-
188-3p, resulting in an upregulation of the miR-188-3p target gene
ATG7, a promoter of autophagy. APF is important in determining
myocardial I/R injury. Because inhibition of autophagy can be protec-
tive in the setting of MI, both APF and miR-188-3p represent poten-
tial targets for therapy.125
Several studies have identiﬁed lncRNAs involved in limb ischemia.
Inhibition of MALAT1 using GapmeRs led to worse outcomes
following experimental hindlimb ischemia. This suggested the possi-
bility that MALAT1 plays a reparative, proangiogenic role.17 More-
over, SENCRwas found to be reduced in human critical limb ischemia
muscles.38 Several additional lncRNAs, includingH19, were identiﬁed
as differentially expressed in normoxic versus hypoxic ECs, followed
by expressional and functional validation in the mouse limb ischemia
model.66
Heart Failure
Heart failure is a complex condition of declined cardiac function in
response to various pathophysiological stresses that cause cardiac
remodeling, characterized by maladaptive hypertrophy. Maladap-
tive remodeling in the failing heart is considered an important
target for therapy, and several lncRNAs are implicated in this
process.126,127
CHRF (cardiac hypertrophy-related factor), which is conserved be-
tween humans and mice, stimulates cardiac hypertrophy and was
the ﬁrst lncRNA reported to have implications in heart failure.126 It
acts as a sponge to miR-489, hence upregulating its downstream
target, MYD88, which is a key gene in activating cardiac hypertro-
phy.126 This was observed in cardiomyocytes of mice with pressure
overload-induced cardiac hypertrophy, but the authors also reported
a natural overexpression of CHRF in human heart failure tissue,
emphasizing that this transcript may have a similar function in
human.126
The heart-enriched lncRNA Chaer (cardiac hypertrophy-associated
epigenetic regulator) is also required for cardiac hypertrophy and is
functionally conserved between mouse and human.128 By interacting
with PRC2, Chaer inhibits histone lysine methylation at the promoter
regions of pro-hypertrophic genes, thus allowing their expression.128Similarly, CHAST (cardiac hypertrophy-associated transcript) plays a
role in promoting hypertrophy and is functionally conserved.15
CHAST levels were endogenously increased during cardiac hypertro-
phy in mice and in hypertrophic heart tissue from patients with aortic
stenosis, a cause of cardiac hypertrophy and ﬁbrosis. Induced overex-
pression of Chast in mice led to cardiomyocyte hypertrophy, while its
suppression attenuated remodeling and hypertrophy without signs of
toxicity.15 This is one of the most prominent examples of the strong
therapeutic potential of lncRNAs for cardiac remodeling, showing
that manipulation of a speciﬁc lncRNA can improve cardiac function.
A study identiﬁed in mice a cluster of cardiac-speciﬁc lncRNAs
termed Mhrt (myosin heavy-chain-associated RNA transcripts) that
are transcribed from the Myh7 locus, which is critical for cardiac
contraction.129 Besides being transcribed from the same locus as
b-RNA (antisense lncRNA involved in cardiac development), the
transcripts have different sequences. Although highly expressed in
adult hearts, Mhrt transcripts were suppressed during pathological
stress. Induced restoration ofMhrt levels prevented cardiac hypertro-
phy and failure, revealing their cardio-protective role. Mhrt acts as a
decoy to inhibit the aberrant expression of pathogenic genes involved
in cardiac contractility, thus maintaining cardiac function. Finally, the
authors found that the human version of MHRT was repressed in
different cardiomyopathies (hypertrophic, ischemic, or idiopathic),
indicating a conserved mechanism.129 This study provides further ev-
idence in support of lncRNAs as potential therapeutic targets, for
which development of a related therapy is facilitated by the conserved
epigenetic regulation in human and mouse.
It has been uncovered that the lncRNA ROR (regulator of reprogram-
ming) plays a role in cardiac hypertrophy. This transcript was natu-
rally overexpressed in murine hypertrophic heart and cardiomyo-
cytes, and its knockdown with siRNA attenuated hypertrophy. ROR
enhanced cardiac hypertrophy by interacting with miR-133, a mus-
cle-enriched miRNA that plays a role in hypertrophy.130 Both RNA
molecules could be investigated as anti-hypertrophic therapeutic
targets.
The circRNA Hrcr (heart-related circular RNA) has a protective role
in cardiac hypertrophy and heart failure in mice. It acts as an endog-
enous sponge for miR-223, thus upregulating the expression of ARC
(apoptosis repressor with caspase recruitment domain).117 ARC
protein is normally highly expressed in the heart and is involved in
cardiomyocyte hypertrophy and apoptosis.131,132 Overexpression of
miR-223 in mice using adenovirus-induced cardiac hypertrophy,
and levels of Hrcr were downregulated in failing mouse hearts, indi-
cating thatHrcrmight constitute another target to treat heart failure if
the mechanism is conserved in humans.117
Therapeutic Applications of lncRNAs
Although lncRNAs offer a multitude of prospective targets due to the
diversity of actions and cellular processes implicated, few practical ex-
amples of therapeutic applications of lncRNAs have been reported so
far. The up- or downregulation of speciﬁc lncRNA abundance haveMolecular Therapy: Nucleic Acids Vol. 8 September 2017 501
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regulation of lncRNAs include the use of recombinant adeno- or len-
tiviruses. Adeno-associated viral (AAV) vectors may represent amore
promising approach due to their low pathogenicity.133–136 This strat-
egy used for targeting miRNAs in preclinical models showed prom-
ising results137–139 and reached successful clinical trials to deliver
protein coding genes,133,140,141 but its use to deliver lncRNAs remains
to be determined.
lncRNA downregulation can be obtained using shRNA or siRNA,
more suitable for cytoplasmic lncRNAs,142 antisense oligonucleotides
(ASOs)-mediated knockdown using aptamers,143 or GapmeRs form-
ing heteroduplexes with their target lncRNAs that are then recognized
and cleaved by the RNase H.144 The latter application, more suitable
for nuclear lncRNAs and with fewer off-target effects than shRNA,145
is already undergoing testing in cell and animal models,15,17,18 while
ASO and siRNA have been used to depleteMALAT1 in human cancer
cells and animal models, reducing metastasis.146–148 Hopefully, it will
be possible to transfer some ﬁndings in other diseases to help accel-
erate the development of therapies for cardiovascular disease. Ribo-
zymes or deoxyribozymes, catalyzing the cleavage of the ﬂanked
region of the RNA target, represent an additional tool to knock
down lncRNAs.149,150 Finally, small molecules that compete with
ligands to bind lncRNAs or induce conformational change in
lncRNAs are being identiﬁed through large screening efforts.151
The most promising lncRNA targets for therapeutic applications in
cardiovascular disease are those for which mechanism of action and
effect are well described and preferably cell speciﬁc. One example is
CHAST, for which the GapmeR-mediated silencing attenuated trans-
verse aortic constriction-induced cardiac remodeling in mice.15 No
apparent side effects were observed due to treatment with GapmeRs.
Future experiments will determine whether cardiac hypertrophic re-
modeling may similarly be targeted through the downregulation of
CHRF, which regulates Myd88, a factor associated with hypertrophy
development,126 or by restoring expression levels ofMHRT, thus pre-
venting cardiomyopathy by restricting stress-associated aberrant
gene expression mediated by the chromatin-remodeling factor,
Brg1.129 Other approaches to decrease cardiac cell death following
MI could target apoptotic or autophagic processes by downregulating
APF.125 In vascular disease, prevention of MALAT1 upregulation
could be used as anti-angiogenic therapy to prevent diabetes-associ-
ated microvascular complications.17,90,91
Challenges and Next Steps
As interest in the role of lncRNAs increases and technology to
detect them becomes more sophisticated, widespread use of RNA
sequencing (RNA-seq) screens has identiﬁed promising candidates
for therapy. lncRNAs potentially represent a powerful tool for
personalized medicine due to their speciﬁc expression patterns asso-
ciated with distinct pathologies. The detection of lncRNAs in circu-
lating exosomes152 opened interesting perspectives both scientiﬁcally,
in terms of signaling regulation and intercellular communication, and
for further translational applications to diagnostics.502 Molecular Therapy: Nucleic Acids Vol. 8 September 2017Several limitations and challenges remain to be resolved before
lncRNAs can reach clinical application. Foremost is target speciﬁcity,
given the pleiotropic implications of a single lncRNA in pathophysi-
ological processes throughout the human body. Although lncRNAs
may show dysregulation speciﬁc to certain diseases, they exhibit
various functions in the organism and some lncRNAs may act
through more than one mechanism. As an example, modulation of
ANRIL, for which SNPs are associated with CAD,106,153 is probably
hazardous given its implication in cancer development and
progression.154,155
Second, the low conservation of lncRNAs across evolution156 makes
both the identiﬁcation of human lncRNAs and their clinical testing
real challenges, because rodents may not be an adequate model.
The hurdles to translate animal ﬁndings to human are illustrated by
Mirt1 and Mirt2, which may have a protective role in LV function,
but no homologs in human have been described so far.110 However,
it has been suggested that it is the secondary structure of lncRNAs
that is conserved and functional, rather than the primary sequence.
For example, GAS5 acting as decoy or signal may depend on its sec-
ondary structures and their afﬁnities for different ligands.157,158 This
may explain why some lncRNAs with important mechanistic roles
have not been observed in other species. If structure is more critical
to function than sequence, then lncRNAs previously considered
non-conserved may have structural homologs in other species, which
would enable the use of existing animal models.
Third, before therapeutic application, the structure-function relation-
ship of each lncRNA must be further elucidated, using newly devel-
oped methods to resolve secondary and tertiary structures.24,159,160
Finally, treatments must ensure the tissue-speciﬁc delivery of the
ASOs or pharmacological agents, as well as their penetration
into the intracellular compartment of interest. The translation of
lncRNA-based therapy into clinical applications should also consider
challenges such as route of delivery, low immunogenicity of the deliv-
ery system, stability of RNA drug in both circulation and cells, dura-
tion of treatment, dosage adjustment, and off-target effects.
Future work is required for a thorough functional characterization of
lncRNAs in cardiovascular pathology, both at the molecular and at
the cellular level. The role of lncRNAs as epigenetic regulators is crit-
ical for gene regulation and disease pathogenesis, yet the ﬁne molec-
ular mechanisms involved remain to be fully elucidated. Although
several RNA-seq experiments have been conducted and many poten-
tial candidates have been identiﬁed,27,66,83,152,161 few have been sufﬁ-
ciently characterized, either in terms of regulation of the disease or in
the ability to be externally regulated. Therefore, much remains to be
done to retrieve the most promising candidates for therapeutic devel-
opment from the huge amount of sequencing data available.
The involvement of circRNAs in cardiovascular pathologies has
emerged.113,117,162 Although appealing due to their resistance to
degradation by exoribonucleases, their use as therapeutic targets re-
quires further investigation. Considering the number of previously
www.moleculartherapy.org
Reviewcharacterized circRNAs and the plethora of circRNAs that remain to
be characterized, this new branch of the ncRNA family constitutes an
invaluable reservoir of therapeutic targets and may be useful to move
theranostics a step forward, because they may be used for both diag-
nostics (biomarkers) and therapeutic purposes. Finally, gene editing
with the CRISPR system appeared as an appealing approach for ther-
apy, and a study reported an efﬁcient downregulation of MALAT1
with this system,163 representing a potential tool for therapeutic ap-
plications in cardiac disease through modulation of the expression
of lncRNAs.
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